Northwell Health | Strategic Alliance Partners

January 31, 2025

In this last episode, experts underscore the importance of incorporating the patient voice into clinical trial processes.

January 31, 2025

In this episode, experts discuss the growth and strategic development of Northwell's cancer clinical trial programs.

January 31, 2025

In this episode, experts discuss how artificial intelligence tools can enhance clinical trial recruitment, improve workforce efficiency, and more.

January 30, 2025

In this episode, experts highlight the increasing push to simplify cancer trial eligibility criteria and improve diversity in participant enrollment.

January 30, 2025

In this episode, experts discuss progress in cancer clinical trials and the challenges posed by the increasing complexity of therapies and protocols.

January 30, 2025

In this episode, experts emphasize the importance of providing flexible clinical trial options, such as satellite sites and remote follow-ups.

January 29, 2025

In this episode, experts discuss the challenges of increasing awareness and participation in clinical trials.

January 28, 2025

In this episode, experts discuss the importance of integrating clinical trials as a standard of care, particularly in the realm of oncology.

December 04, 2024

Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.

November 08, 2024

Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.

October 25, 2024

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.

July 24, 2024

New START early-phase clinical trial site brings advanced cancer research to Northwell’s Cancer Institute, increases patient access

January 03, 2024

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

December 27, 2023

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

December 27, 2023

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

December 20, 2023

Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.

December 20, 2023

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

December 13, 2023

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.

December 13, 2023

Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.

December 06, 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.